
    
      Healthy volunteers are administrated single-dose over the period I and II (crossover) of
      SYP-1512 Tab and Revlimid cap (25mg) as of lenalidomide 25mg.

      Every time before and after each medication, pharmacokinetic (PK) parameters and safety of
      SYP-1512 Tab and Revlimid cap (25mg) is performed using a blood sample and conducting some
      tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively
    
  